Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer

Andrea Alimonti, Chiara Nardoni, Paola Papaldo, Gianluigi Ferretti, Maria Pia Caleno, Paolo Carlini, Alessandra Fabi, Debora Rasio, Aldo Vecchione, Francesco Cognetti

Research output: Contribution to journalArticle

Abstract

Ixabepilone (Ix) (BMS-247550®) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. In pre-clinical studies, Ix has shown anticancer activity against several cancer types, including paclitaxel-resistant models, both in vitro and in vivo. The major toxicities associated with Ix are myelosuppression, sensory neuropathy and neutropenia. Other minor side-effects include asthenia/fatigue, stomatitis, anorexia, alopecia, skin reaction, hypersensitivity reactions and a fluid-retention syndrome. Although Ix is functionally correlated to taxanes, no previous evidence exists regarding Ix-related nail disorders. Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails.

Original languageEnglish
Pages (from-to)3531-3532
Number of pages2
JournalAnticancer Research
Volume25
Issue number5
Publication statusPublished - Sep 2005

Fingerprint

Nails
Breast Neoplasms
Onycholysis
Epothilones
Asthenia
Taxoids
Stomatitis
Excipients
Alopecia
Cytotoxins
Anorexia
Paclitaxel
ixabepilone
Neutropenia
Microtubules
Fatigue
Hypersensitivity
Skin
Neoplasms

Keywords

  • Breast cancer
  • Ixabepilone
  • Nail disorders

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alimonti, A., Nardoni, C., Papaldo, P., Ferretti, G., Caleno, M. P., Carlini, P., ... Cognetti, F. (2005). Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer. Anticancer Research, 25(5), 3531-3532.

Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer. / Alimonti, Andrea; Nardoni, Chiara; Papaldo, Paola; Ferretti, Gianluigi; Caleno, Maria Pia; Carlini, Paolo; Fabi, Alessandra; Rasio, Debora; Vecchione, Aldo; Cognetti, Francesco.

In: Anticancer Research, Vol. 25, No. 5, 09.2005, p. 3531-3532.

Research output: Contribution to journalArticle

Alimonti, A, Nardoni, C, Papaldo, P, Ferretti, G, Caleno, MP, Carlini, P, Fabi, A, Rasio, D, Vecchione, A & Cognetti, F 2005, 'Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer', Anticancer Research, vol. 25, no. 5, pp. 3531-3532.
Alimonti A, Nardoni C, Papaldo P, Ferretti G, Caleno MP, Carlini P et al. Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer. Anticancer Research. 2005 Sep;25(5):3531-3532.
Alimonti, Andrea ; Nardoni, Chiara ; Papaldo, Paola ; Ferretti, Gianluigi ; Caleno, Maria Pia ; Carlini, Paolo ; Fabi, Alessandra ; Rasio, Debora ; Vecchione, Aldo ; Cognetti, Francesco. / Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer. In: Anticancer Research. 2005 ; Vol. 25, No. 5. pp. 3531-3532.
@article{a19266b040244c65b98637ac9744ddb4,
title = "Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer",
abstract = "Ixabepilone (Ix) (BMS-247550{\circledR}) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. In pre-clinical studies, Ix has shown anticancer activity against several cancer types, including paclitaxel-resistant models, both in vitro and in vivo. The major toxicities associated with Ix are myelosuppression, sensory neuropathy and neutropenia. Other minor side-effects include asthenia/fatigue, stomatitis, anorexia, alopecia, skin reaction, hypersensitivity reactions and a fluid-retention syndrome. Although Ix is functionally correlated to taxanes, no previous evidence exists regarding Ix-related nail disorders. Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails.",
keywords = "Breast cancer, Ixabepilone, Nail disorders",
author = "Andrea Alimonti and Chiara Nardoni and Paola Papaldo and Gianluigi Ferretti and Caleno, {Maria Pia} and Paolo Carlini and Alessandra Fabi and Debora Rasio and Aldo Vecchione and Francesco Cognetti",
year = "2005",
month = "9",
language = "English",
volume = "25",
pages = "3531--3532",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Nail disorders in a woman treated with Ixabepilone for metastatic breast cancer

AU - Alimonti, Andrea

AU - Nardoni, Chiara

AU - Papaldo, Paola

AU - Ferretti, Gianluigi

AU - Caleno, Maria Pia

AU - Carlini, Paolo

AU - Fabi, Alessandra

AU - Rasio, Debora

AU - Vecchione, Aldo

AU - Cognetti, Francesco

PY - 2005/9

Y1 - 2005/9

N2 - Ixabepilone (Ix) (BMS-247550®) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. In pre-clinical studies, Ix has shown anticancer activity against several cancer types, including paclitaxel-resistant models, both in vitro and in vivo. The major toxicities associated with Ix are myelosuppression, sensory neuropathy and neutropenia. Other minor side-effects include asthenia/fatigue, stomatitis, anorexia, alopecia, skin reaction, hypersensitivity reactions and a fluid-retention syndrome. Although Ix is functionally correlated to taxanes, no previous evidence exists regarding Ix-related nail disorders. Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails.

AB - Ixabepilone (Ix) (BMS-247550®) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. In pre-clinical studies, Ix has shown anticancer activity against several cancer types, including paclitaxel-resistant models, both in vitro and in vivo. The major toxicities associated with Ix are myelosuppression, sensory neuropathy and neutropenia. Other minor side-effects include asthenia/fatigue, stomatitis, anorexia, alopecia, skin reaction, hypersensitivity reactions and a fluid-retention syndrome. Although Ix is functionally correlated to taxanes, no previous evidence exists regarding Ix-related nail disorders. Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails.

KW - Breast cancer

KW - Ixabepilone

KW - Nail disorders

UR - http://www.scopus.com/inward/record.url?scp=23344442700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344442700&partnerID=8YFLogxK

M3 - Article

C2 - 16101175

AN - SCOPUS:23344442700

VL - 25

SP - 3531

EP - 3532

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -